Christiane Mounier
Saint-priest-la-vetre, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 18, 2023
Dysregulated pathways and differentially expressed proteins associated with adverse transfusion reactions in different types of platelet components.
Journal: Journal of proteomics
Published: October 15, 2019
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Journal: Haematologica
Published: February 23, 2018
Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: February 03, 2018
Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 15, 2016
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 21, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026